Stute P, Becker H-G, Bitzer J, Chatsiproios D, Luzuy F, von Wolff M, Wunder D, Birkhäuser M
Department of Obstetrics and Gynecology, University of Berne.
Climacteric. 2015 Apr;18(2):182-6. doi: 10.3109/13697137.2014.975198. Epub 2014 Dec 4.
Despite increasing life expectancy, the age of onset of natural menopause has not significantly changed in recent decades. Thus, women spend about one-third of their lives in an estrogen-deficient state if untreated. There is a need for appropriate treatment of acute symptoms and prevention of the sequelae of chronic estrogen deficiency. International guidelines call for the use of the lowest effective hormone dosage for vasomotor symptom relief, the major indication for menopausal hormone therapy (MHT). In 2011, an oral continuous combined ultra-low-dose MHT was approved in Switzerland. This publication was elaborated by eight national menopause specialists and intends to review the advantages and disadvantages of ultra-low-dose MHT after the first years of its general use in Switzerland. It concludes that, for many women, ultra-low-dose MHT may be sufficient to decrease vasomotor symptoms, but not necessarily to guarantee fracture prevention.
尽管预期寿命在增加，但近几十年来自然绝经的发病年龄并未显著改变。因此，如果不进行治疗，女性一生中约三分之一的时间处于雌激素缺乏状态。需要对急性症状进行适当治疗，并预防慢性雌激素缺乏的后遗症。国际指南要求使用最低有效激素剂量来缓解血管舒缩症状，这是更年期激素治疗（MHT）的主要适应症。2011年，一种口服连续联合超低剂量MHT在瑞士获得批准。本出版物由八位国家更年期专家精心撰写，旨在回顾超低剂量MHT在瑞士广泛使用头几年后的优缺点。结论是，对许多女性来说，超低剂量MHT可能足以减轻血管舒缩症状，但不一定能保证预防骨折。
